Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Pre-clinical Studies of Personalized Medicine for Cancer Research
share announcement

Pre-clinical Studies of Personalized Medicine for Cancer Research

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 4961

Special Issue Editor

Prof. Dr. Nuno Vale

E-Mail Website
Guest Editor
Department of Community Medicine, Health Information and Decision, Faculty of Medicine, University of Porto, Rua Dr. Plácido da Costa, 4200-450, Porto, Portugal
Interests: in silico pharmacology; PBPK; drug metabolism; drug combination; drug delivery; peptides; ADME; DMPK; pharmacokinetic
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pre-clinical studies of personalized medicine for cancer involve the exploration and development of targeted therapies and treatment strategies that are tailored to the unique genetic and molecular characteristics of an individual's cancer. These studies play a crucial role in advancing the field of oncology by providing valuable insights into the efficacy, safety, and potential side effects of personalized treatments before they are tested in human clinical trials.

This Special Issue is dedicated to key aspects of pre-clinical studies for personalized medicine in cancer research, for patent-derived models (which can include cell lines, xenografts (tumors grown in mice using patient-derived cells), or organoids (3D cultures of cancer cells that mimic the original tumor)), genomic profiling (specific mutations, alterations, and biomarkers that may be targeted by personalized therapies), drug screening (targeted therapies, immunotherapies, and conventional chemotherapeutics, or drug repurposing), biomarker validation (identified through genomic profiling), combination therapies (synergies between different drugs or treatment modalities), toxicity and safety assessment (understanding the therapeutic window and ensuring that the treatment is safe for patients), mechanistic studies (how specific drugs interact with molecular targets and pathways within cancer cells), tumor heterogeneity (pre-clinical studies taking into account the heterogeneity of tumors, recognizing that different regions of a tumor may have distinct genetic profiles), animal studies (understanding how treatments perform in a whole organism and providing insights into potential systemic effects), and data analysis interpretation (statistical methods and bioinformatics play a crucial role in the effectiveness and safety of personalized treatments).

In this Special Issue, original articles and reviews would be highly appreciated.

I look forward to receiving your contributions.

Prof. Dr. Nuno Vale
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • patient-derived models
  • genomic profiling
  • drug screening
  • biomarker validation
  • combination therapies
  • mechanistic studies
  • tumor heterogeneity
  • data analysis and interpretation

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

19 pages, 1722 KiB  
Review
Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention
by Hayato Muranaka, Rasaq Akinsola, Sandrine Billet, Stephen J. Pandol, Andrew E. Hendifar, Neil A. Bhowmick and Jun Gong
Cancers 2024, 16(5), 1057; https://doi.org/10.3390/cancers16051057 - 05 Mar 2024
Viewed by 1602
Abstract
Glutamine, a multifaceted nonessential/conditionally essential amino acid integral to cellular metabolism and immune function, holds pivotal importance in the landscape of cancer therapy. This review delves into the intricate dynamics surrounding both glutamine antagonism strategies and glutamine supplementation within the context of cancer [...] Read more.
Glutamine, a multifaceted nonessential/conditionally essential amino acid integral to cellular metabolism and immune function, holds pivotal importance in the landscape of cancer therapy. This review delves into the intricate dynamics surrounding both glutamine antagonism strategies and glutamine supplementation within the context of cancer treatment, emphasizing the critical role of glutamine metabolism in cancer progression and therapy. Glutamine antagonism, aiming to disrupt tumor growth by targeting critical metabolic pathways, is challenged by the adaptive nature of cancer cells and the complex metabolic microenvironment, potentially compromising its therapeutic efficacy. In contrast, glutamine supplementation supports immune function, improves gut integrity, alleviates treatment-related toxicities, and improves patient well-being. Moreover, recent studies highlighted its contributions to epigenetic regulation within cancer cells and its potential to bolster anti-cancer immune functions. However, glutamine implementation necessitates careful consideration of potential interactions with ongoing treatment regimens and the delicate equilibrium between supporting normal cellular function and promoting tumorigenesis. By critically assessing the implications of both glutamine antagonism strategies and glutamine supplementation, this review aims to offer comprehensive insights into potential therapeutic strategies targeting glutamine metabolism for effective cancer management. Full article
(This article belongs to the Special Issue Pre-clinical Studies of Personalized Medicine for Cancer Research)
►▼ Show Figures

Figure 1

11 pages, 265 KiB  
Review
Supplement Use and Increased Risks of Cancer: Unveiling the Other Side of the Coin
by Parnian Jabbari, Omid Yazdanpanah, David J. Benjamin and Arash Rezazadeh Kalebasty
Cancers 2024, 16(5), 880; https://doi.org/10.3390/cancers16050880 - 22 Feb 2024
Viewed by 1381
Abstract
There is a rising trend in the consumption of dietary supplements, especially among adults, with the purpose of improving health. While marketing campaigns tout the potential health benefits of using dietary supplements, it is critical to evaluate the potential harmful effects associated with [...] Read more.
There is a rising trend in the consumption of dietary supplements, especially among adults, with the purpose of improving health. While marketing campaigns tout the potential health benefits of using dietary supplements, it is critical to evaluate the potential harmful effects associated with these supplements as well. The majority of the scarce research on the potential harmful effects of vitamins focuses on the acute or chronic toxicities associated with the use of dietary supplements. Quality research is still required to further investigate the risks of long-term use of dietary supplements, especially the risk of developing cancers. The present review concentrates on studies that have investigated the association between the risk of developing cancers and associated mortality with the risk of dietary supplements. Such an association has been reported for several vitamins, minerals, and other dietary supplements. Even though several of these studies come with their own shortcomings and critics, they must draw attention to further investigate long-term adverse effects of dietary supplements and advise consumers and healthcare providers to ponder the extensive use of dietary supplements. Full article
(This article belongs to the Special Issue Pre-clinical Studies of Personalized Medicine for Cancer Research)
►▼ Show Figures

Graphical abstract

22 pages, 2532 KiB  
Review
Cuproptosis: Unraveling the Mechanisms of Copper-Induced Cell Death and Its Implication in Cancer Therapy
by Chloe Springer, Danish Humayun and Rachid Skouta
Cancers 2024, 16(3), 647; https://doi.org/10.3390/cancers16030647 - 02 Feb 2024
Cited by 1 | Viewed by 1749
Abstract
Copper, an essential element for various biological processes, demands precise regulation to avert detrimental health effects and potential cell toxicity. This paper explores the mechanisms of copper-induced cell death, known as cuproptosis, and its potential health and disease implications, including cancer therapy. Copper [...] Read more.
Copper, an essential element for various biological processes, demands precise regulation to avert detrimental health effects and potential cell toxicity. This paper explores the mechanisms of copper-induced cell death, known as cuproptosis, and its potential health and disease implications, including cancer therapy. Copper ionophores, such as elesclomol and disulfiram, increase intracellular copper levels. This elevation triggers oxidative stress and subsequent cell death, offering potential implications in cancer therapy. Additionally, copper ionophores disrupt mitochondrial respiration and protein lipoylation, further contributing to copper toxicity and cell death. Potential targets and biomarkers are identified, as copper can be targeted to those proteins to trigger cuproptosis. The role of copper in different cancers is discussed to understand targeted cancer therapies using copper nanomaterials, copper ionophores, and copper chelators. Furthermore, the role of copper is explored through diseases such as Wilson and Menkes disease to understand the physiological mechanisms of copper. Exploring cuproptosis presents an opportunity to improve treatments for copper-related disorders and various cancers, with the potential to bring significant advancements to modern medicine. Full article
(This article belongs to the Special Issue Pre-clinical Studies of Personalized Medicine for Cancer Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop